Galectin Therapeutics (GALT) Tops Q2 EPS by 4c

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• ZTO Express (ZTO) Tops Q2 EPS by 379c
• Full Truck Alliance (YMM) Tops Q2 EPS by 10c; beats on guidance